This trial is testing a new combo - CC-92480, bortezomib, and dexamethasone - against the standard of care - pomalidomide, bortezomib, and dexamethasone - for patients with multiple myeloma who have failed 1-3 prior treatments and have been treated with lenalidomide before.
- Relapsed or Refractory Multiple Myeloma
1 Primary · 15 Secondary · Reporting Duration: Up to approximately 5 years
Awards & Highlights
2 Treatment Groups
PVd (pomalidomide, bortezomib and dexamethasone)
1 of 2
480Vd (CC-92480, bortezomib and dexamethasone)
1 of 2
760 Total Participants · 2 Treatment Groups
Primary Treatment: CC-92480 · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||100.0%|
Frequently Asked Questions
What has been observed in patients taking CC-92480?
"There is both preclinical and clinical evidence supporting CC-92480's safety, thus it received a score of 3." - Anonymous Online Contributor
Could you name how many places this research project is being conducted?
"Patients can be enrolled at the Local Institution in Hattiesburg, Mississippi, Utah Cancer Specialists in Salt Lake City, Utah, Northwell Health Clinical Trials Office in Lake Success, New York, and 18 other locations." - Anonymous Online Contributor
Can people sign up for this research project at the present moment?
"This study, as indicated on clinicaltrials.gov, is currently seeking participants. The trial was originally posted on September 20th, 2022 and was most recently updated on October 24th, 2022." - Anonymous Online Contributor